Literature DB >> 21238827

D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study.

Laurel E Fohn1, Adrian Rodriguez, Mark C Kelley, Fei Ye, Yu Shyr, George Stricklin, Jason B Robbins.   

Abstract

BACKGROUND: Sentinel lymph node (SLN) status is the greatest prognostic factor of morbidity in melanoma. D2-40 antibody specifically marks lymphatic endothelium and has been used for identifying lymphatic invasion (LI) in multiple cancers.
OBJECTIVE: We sought to determine the relationship between melanoma lymphatic invasion (as detected using D2-40 on primary melanoma biopsies/excisions) and the presence or absence of melanoma in subsequent SLN biopsy.
METHODS: We retrospectively evaluated LI using D2-40 on primary biopsies/excisions from patients with thin to intermediate thickness (Breslow thickness: ≤2.0 mm) melanomas, who underwent lymphatic mapping and SLN biopsy, and whose SLN status was known. Sixty-four cases met the criteria and were available for analysis. We analyzed patient age, patient sex, mitotic rate, ulceration, tumor depth, and D2-40 detected LI as predictors of SLN status.
RESULTS: Lymphatic invasion detection increased from 3.1% using hematoxylin and eosin only to 21.9% using D2-40. Twelve of 14 patients with D2-40 LI were SLN positive (positive predictive value, 85.7%). D2-40 LI was detected in the primary biopsy specimen of 12 of 18 patients with a positive SLN (sensitivity 66.7%). Of 50 patients without D2-40 LI, 44 were SLN negative (negative predictive value, 88.0%). Of 46 SLN-negative patients, 44 did not have D2-40 LI (specificity, 95.7%). LIMITATIONS: Results are retrospective and limited to SLN biopsy performed at one institution.
CONCLUSIONS: On univariate and multivariate analysis, D2-40-detected LI was the most significant predictor of SLN status. D2-40 antibody staining to detect lymphatic invasion should be incorporated in routine melanoma biopsy evaluation. Copyright Â
© 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21238827     DOI: 10.1016/j.jaad.2010.03.005

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Authors:  Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger
Journal:  Am J Clin Dermatol       Date:  2020-02       Impact factor: 7.403

2.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

3.  Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma.

Authors:  Xiaowei Xu; Phyllis A Gimotty; Dupont Guerry; Giorgos Karakousis; David E Elder
Journal:  Methods Mol Biol       Date:  2014

4.  Lymphatic invasion and angiotropism in primary cutaneous melanoma.

Authors:  Andrea P Moy; Lyn M Duncan; Stefan Kraft
Journal:  Lab Invest       Date:  2016-12-19       Impact factor: 5.662

Review 5.  Review of diagnostic, prognostic, and predictive biomarkers in melanoma.

Authors:  Jacob S Ankeny; Brian Labadie; Jason Luke; Eddy Hsueh; Jane Messina; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

6.  Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer.

Authors:  Qiu-Wan Wu; Hong-Qiang She; Jing Liang; Yu-Fan Huang; Qing-Mo Yang; Qiao-Lu Yang; Zhi-Ming Zhang
Journal:  BMC Cancer       Date:  2012-01-27       Impact factor: 4.430

7.  Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma.

Authors:  Sarah J Storr; Sabreena Safuan; Angana Mitra; Faye Elliott; Christopher Walker; Mark J Vasko; Bernard Ho; Martin Cook; Rabab A A Mohammed; Poulam M Patel; Ian O Ellis; Julia A Newton-Bishop; Stewart G Martin
Journal:  Mod Pathol       Date:  2011-11-11       Impact factor: 7.842

8.  Expression and clinical significance of matrix metalloproteinase-9 in lymphatic invasiveness and metastasis of breast cancer.

Authors:  Qiu-Wan Wu; Qing-Mo Yang; Yu-Fan Huang; Hong-Qiang She; Jing Liang; Qiao-Lu Yang; Zhi-Ming Zhang
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

9.  Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer.

Authors:  Matthew G Davey; Éanna J Ryan; Daniel Burke; Kevin McKevitt; Peter F McAnena; Michael J Kerin; Aoife J Lowery
Journal:  Breast Cancer (Auckl)       Date:  2021-06-14

10.  Extracellular matrix protein 1 is correlated to carcinogenesis and lymphatic metastasis of human gastric cancer.

Authors:  Qiuwan Wu; Xiaohong Li; Haiyan Yang; Chuanhui Lu; Jun You; Zhiming Zhang
Journal:  World J Surg Oncol       Date:  2014-04-29       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.